Home/Pipeline/CINVANTI®

CINVANTI®

Chemotherapy-Induced Nausea and Vomiting (CINV)

ApprovedMarketed

Key Facts

Indication
Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase
Approved
Status
Marketed
Company

About Heron Therapeutics

Heron Therapeutics is a fully integrated biopharmaceutical company with a mission to improve patient lives through best-in-class, non-opioid medicines. The company has successfully commercialized a portfolio of four products targeting postoperative pain (ZYNRELEF®) and nausea/vomiting (SUSTOL®, CINVANTI®, APONVIE®), leveraging its proprietary Biochronomer® drug delivery technology to create sustained-release formulations. Its strategy focuses on addressing significant unmet needs in acute and oncology care by providing long-duration, localized therapy from a single administration, thereby reducing systemic side effects and healthcare burdens associated with opioid use and uncontrolled symptoms.

View full company profile

Other Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs

DrugCompanyPhase
AKYNZEO® Oral SuspensionHelsinnApproved
SUSTOL®Heron TherapeuticsApproved